Amyloid Beta Articles & Analysis
17 news found
With a focus on oral, small molecule, tau inhibitors that block tau self-association in the early steps of the tau aggregation cascade, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective and could complement both tau and beta-amyloid antibody treatment. Oligomerix is headquartered ...
The studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected. ...
Recent research has demonstrated that proteins such as tau and beta amyloid accumulate to not only cause neuronal cell death, but also create abnormal electrical activity in the brain. ...
(Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. ...
ByVaxxinit
The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease. ...
With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that ...
Separately, a group of leading researchers[1] presented their round-robin findings that measuring amyloid beta (Aβ) in a patient’s blood can be a pre-screen or a substitute for costly PET scans or invasive cerebrospinal fluid (also known as spinal tap) screenings that clinicians use to diagnose Alzheimer’s disease. ...
” The FDA said, “Patients receiving the [aducanumab] treatment had significant dose- and time-dependent reduction of amyloid beta plaque, while patients in the control arm of the studies had no reduction of amyloid beta ...
The article is titled “The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis”; it states that the “analytical validation experiments document excellent precision, a wide linear range, low limit of detection, and ...
” PrecivityAD™ Blood Test Relies on Proprietary Platform The PrecivityAD™ test identifies whether a patient is likely to have amyloid plaques in the brain. The test relies on precise quantitation of the amyloid beta 42/40 ratio (Aβ 42/40) and detection of the apolipoprotein E proteotype (equivalent to ...
C2N analyzes the blood in its specialized laboratory facility using mass spectrometry to measure the concentrations of amyloid beta 42 and 40 (Aβ42 and Aβ40), and the presence of apolipoprotein E (ApoE) isoforms in blood. ...
Most clinical studies for AD have focused on amyloid beta but have had limited success in patients. There continues to be mounting evidence that tau pathology drives neurodegeneration in diseases like AD, frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). ...
Sleep deprivation robs the brain of a crucial protein called amyloid beta, which results in a plaque buildup that’s similarly seen in cat scans of patients with Alzheimer’s. ...
Research published in the Journal of Alzheimer’s Disease this week suggests healthy older adults are less capable of observing their own cognitive decline over an 18 month period than Cogstate’s computerized brief battery (CBB). The study, conducted by neuropsychologists, also indicated that close family members were unable to perceive decline in the cognitive behavior of their ...
Yakel said the findings are also a potentially important step in the study of disorders that affect learning and memory, such as Alzheimer's disease and schizophrenia, where the acetylcholine system and hippocampus are known to play critical roles. For example, amyloid beta peptide is the major component of plaques that form in the brains of Alzheimer's patients ...
Yakel said the findings are also a potentially important step in the study of disorders that affect learning and memory, such as Alzheimer's disease and schizophrenia, where the acetylcholine system and hippocampus are known to play critical roles. For example, amyloid beta peptide is the major component of plaques that form in the brains of Alzheimer's patients ...
Alzheimer’s disease is associated with the development of a toxic protein in the brain known as amyloid beta. The amyloid beta protein rapidly self-assembles in the brain and builds up to form plaques which are a hallmark of the disease. ...